These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22804569)

  • 21. Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease.
    Howard LM; Miller SD
    Autoimmunity; 2004 Aug; 37(5):411-8. PubMed ID: 15621565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine.
    Hangalapura BN; Oosterhoff D; de Groot J; Boon L; Tüting T; van den Eertwegh AJ; Gerritsen WR; van Beusechem VW; Pereboev A; Curiel DT; Scheper RJ; de Gruijl TD
    Cancer Res; 2011 Sep; 71(17):5827-37. PubMed ID: 21747119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B-Lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumour immune response by direct and indirect activation of CD8(+) T-cells.
    Ritchie DS; Yang J; Hermans IF; Ronchese F
    Scand J Immunol; 2004 Dec; 60(6):543-51. PubMed ID: 15584965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on CD40 and CD154 blockade in transplant models.
    Zhang T; Pierson RN; Azimzadeh AM
    Immunotherapy; 2015; 7(8):899-911. PubMed ID: 26268734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B cells regulate CD40 ligand-induced IL-12 production in antigen-presenting cells (APC) during T cell/APC interactions.
    Maruo S; Oh-hora M; Ahn HJ; Ono S; Wysocka M; Kaneko Y; Yagita H; Okumura K; Kikutani H; Kishimoto T; Kobayashi M; Hamaoka T; Trinchieri G; Fujiwara H
    J Immunol; 1997 Jan; 158(1):120-6. PubMed ID: 8977182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination with immature dendritic cells combined with CD40mAb induces protective immunity against B lymphoma in hu-SCID mice.
    Ge Y; Xi H; Zhang XG
    Biomed Pharmacother; 2010 Sep; 64(7):487-92. PubMed ID: 20382498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autogeneic rna-electroporated CD40-ligand activated b-cells from hepatocellular carcinoma patients induce CD8+ T-cell responses ex vivo.
    Shen S; Xu Z; Qian X; Ding Y; Yu L; Liu B
    Exp Oncol; 2007 Jun; 29(2):137-43. PubMed ID: 17704747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector.
    Kimura T; Ohashi T; Kikuchi T; Kiyota H; Eto Y; Ohishi Y
    Cancer Gene Ther; 2003 Nov; 10(11):833-9. PubMed ID: 14605669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LTβR and CD40: working together in dendritic cells to optimize immune responses.
    Gommerman JL; Summers deLuca L
    Immunol Rev; 2011 Nov; 244(1):85-98. PubMed ID: 22017433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
    Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
    Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accessory signaling by CD40 for T cell activation: induction of Th1 and Th2 cytokines and synergy with interleukin-12 for interferon-gamma production.
    Peng X; Kasran A; Warmerdam PA; de Boer M; Ceuppens JL
    Eur J Immunol; 1996 Jul; 26(7):1621-7. PubMed ID: 8766570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
    Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
    Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory T cells and minimal change nephropathy: in the midst of a complex network.
    Bertelli R; Bonanni A; Di Donato A; Cioni M; Ravani P; Ghiggeri GM
    Clin Exp Immunol; 2016 Feb; 183(2):166-74. PubMed ID: 26147676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged.
    Tang YC; Thoman M; Linton PJ; Deisseroth A
    Cancer Immunol Immunother; 2009 Dec; 58(12):1949-57. PubMed ID: 19444444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
    Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P
    Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD40 activation: potential for specific immunotherapy in B-CLL.
    von Bergwelt-Baildon M; Maecker B; Schultze J; Gribben JG
    Ann Oncol; 2004 Jun; 15(6):853-7. PubMed ID: 15151939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.
    Kornbluth RS; Stempniak M; Stone GW
    Int Rev Immunol; 2012 Aug; 31(4):279-88. PubMed ID: 22804572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Harnessing B cells in immunotherapy.
    Cascalho M; Platt JL
    Immunotherapy; 2016; 8(3):237-9. PubMed ID: 26860221
    [No Abstract]   [Full Text] [Related]  

  • 39. Concepts for agonistic targeting of CD40 in immuno-oncology.
    Richards DM; Sefrin JP; Gieffers C; Hill O; Merz C
    Hum Vaccin Immunother; 2020; 16(2):377-387. PubMed ID: 31403344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invasive cryptococcus infections in immunocompetent individuals may suggest defects in CD40/CD40L signaling pathway.
    Khan S
    Indian J Pathol Microbiol; 2009; 52(3):458-9. PubMed ID: 19680004
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.